Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDORA-switch
2019-001754-25Phase 4Completed
- Sponsor
- Reade
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of adalimumab, etanercept, rituximab, abatacept, tocilizumab and 1 more in rheumatoid arthritis (RA) (2 arms), sponsored by Reade. Primary endpoint: Difference in mean time-weighted DAS28-CRP after 28 weeks. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2019-001754-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001754-25.